Can a single drug calm lupus kidney disease without a cocktail of meds?
NCT ID NCT07721363
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase II trial tests whether obinutuzumab, a B-cell targeting antibody, can alone achieve complete kidney response in people with pure class V lupus nephritis—a form of lupus kidney disease with no approved treatments. Participants receive up to four infusions over seven months and are followed for a year. The study aims to see if this approach can reduce protein in the urine and preserve kidney function without the need for other immunosuppressants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- obinutuzumab (also known as GAZYVARO), a B-cell targeting antibody given as intravenous infusions
- What this could lead to
- If successful, this could provide a targeted treatment option for a form of lupus kidney disease that currently has no approved therapy.
- What could go wrong
- This is an early-phase trial with only 65 participants, so results may not apply broadly. Obinutuzumab can cause infusion reactions and increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sorbonne University - Nephrology Départment - Tenon APHP
Paris, France, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app bridge the lupus care gap for women of color?
- Immune cells may hold key to predicting kidney disease relapse
- New antibody targets hidden plasma cells to treat kidney disease
- Cancer drug shows promise for lupus kidney disease
- Engineered immune cells take aim at autoimmune kidney diseases
- New drug combo aims to tame lupus kidney disease in kids